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CHAPTER 1
INTRODUCTION
DEMENTIA
Dementia is not a disease in itself but is a general term used to describe a variety of
diseases and conditions that emerge when nerve cells in the brain die or no longer function
normally. This thereby causes death or malfunction of these nerve cells (neurons), leading to
changes in one’s memory, behavior and cognitive abilities [1]. According to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [2], a patient has dementia
when they present a decline in memory and at least one of the following symptoms:
1) Ability to generate coherent speech or understand spoken or written language.
2) Ability to recognize or identify objects, assuming intact sensory function.
3) Ability to execute motor activities, assuming intact motor abilities and sensory function and
comprehension of the required task.
4) Ability to think abstractly, make sound judgments and plan and carry out complex tasks.
1.1.1 TYPES OF DEMENTIA

There are different types of dementia, categorized by their symptoms and brain
abnormalities [1][2][3].
a. Alzheimer’s disease: This is the most common form of dementia.
Early symptoms: Difficulty remembering names and current events; apathy and depression
Late symptoms: Impaired judgment, disorientation, confusion, behavior changes and
difficulty speaking, swallowing and walking.
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Brain abnormalities: Deposition of beta-amyloid (plaques) and twisted strands of the protein
tau (tangles) along with proof of nerve cell damage and death in the brain.
b. Vascular dementia: This form of dementia was formerly known as multi-infarct or poststroke dementia (dementia secondary to stroke).
Symptoms: Impaired judgment or ability to make plans
Brain abnormality: Localized brain injury leading to microscopic bleeding and blockage of
blood vessels.
c. Dementia with Lewy bodies(DLB): Lewy bodies are abnormal clumps of the protein called
alpha-synuclein.
Symptoms: Vivid hallucinations, sleep disturbances in additions to the symptoms seen in
Alzheimer’s disease.
Brain abnormality: Deposition of alpha-synuclein in the cerebal cortex of the brain.
d. Mixed dementia: As its name goes, it’s symptoms include a combination those seen in
Alzhiemer’s disease, vascular dementia and DLB.
Brain abnormality : There’s more of beta amyloid deposition and injury to the brain seen.
e. Parkinson’s disease: Presentation is similar to that of DLB or Alzheimer’s disease.
Symptoms: Difficulty moving around.
Brain abnormality: Alpha-synuclein is deposited in a deep area of the brain called the
substantia nigra. This deposition is believed to destroy nerve cells that produce dopamine
thereby resulting in Parkinson’s disease.
f. Frontotemporal lobar degeneration (FTLD): There are subtypes of FTLD such as as
behavioral variant FTLD, primary progressive aphasia, Pick’s disease and progressive
supranuclear palsy.
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Symptoms: Difficulty with languages, altered behavior and personality
Brain abnormality: There is no distinct abnormality seen, however the neurons on the front
and side regions of the brain seem to be affected.
g. Creutzfeldt-Jakob disease: There is a variant form of this disease which results from the
feeding on products from cattle infected with the mad cow disease. This disease is rapidly
fatal.
Symptoms: Memory and coordination impairment, altered behavior.
Brain abnormality: Malfunction of protein of the brain. This is as a result of prions
(misfolded proteins) causes other proteins of the brain to misfold.
f. Normal pressure hydrocephalus: This type of dementia can be corrected by the insertion of
a shunt in the brain to drain fluids.
Symptoms: Urinary incontinence, loss of memory and impaired coordination
Brain abnormality: Accumulation of fluid in the brain.
1.1 ALZHIEMER’S DISEASE
Alzheimer’s disease (AD) accounts for 50 to 70 % of dementia presentations. It
was initially identified and brought to light in 1906 by Aloysius ‘Alois’ Alzheimer, a
German psychiatrist and neuropathologist as amyloid plaques (Aβ) and neurofibrillary
tangles (NFTs) from a 51-year old patient named Auguste Deter. This patient presented
impaired mental function with significant cognitive decline [4]. AD is the sixth leading
cause of death in the United States and the fifth leading cause of death in people over the
age of 65, as determined by the Centers for Disease Control and Prevention (CDC) [5].
The risk of developing AD increases exponentially with age. This disease has since been
diagnosed in more than 5.1 million people in the United States alone. In 2015, the direct
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costs to the United States for caring Alzheimer's patients estimated at total of $226
billion, with half of the costs borne by Medicare. People 65 years of age and older with
Alzheimer’s and other dementia spend three times higher on average per-person
Medicare expenses than for seniors without dementia. The Medicaid payments are 19
times higher. Approximately one in every five Medicare dollars is spent on people with
Alzheimer's and other dementias. In 2050, it will be one in every three dollars [6]. There
are two forms of AD; early onset (EOAD) and the late onset also known as sporadic AD
(LOAD/SAD). The late onset AD accounts for about 87% of the cases and early onset
accounts for about 13% of cases. It has stimulated several hypothesis as its possible cause
(although actual process of development is still yet to be understood). It is characterized
by a significant deficit of hippocampal neurons which leads to decrease in cognition,
memory loss ultimately, dementia. There is the cholinergic, tau and amyloid hypothesis,
in our study we explored the amyloid hypothesis [7].

The Cholinergic hypothesis:
It has been discovered that AD patients have low concentrations of acetylcholine.
Acetylcholine is a neurotransmitter that is metabolized by an enzyme ( a serine protease) called
acetylcholine esterase in the central nervous system (CNS) into acetate and choline as seen in
figure 1 below[8]. This chemical serves as a neuro-modulator in the CNS and is located in the
pre-ganglionic and parasympathetic neurons. It is also the neurotransmitter in the sweat glands
and piloerector muscles of the sympathetic autonomic nervous system.
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Figure 1: Breaking down of acetylcholine by acetylcholine esterase.

The brain of mammals contains two major forms of cholinesterases: acetylcholinesterase
(AChE) and butyrylcholinesterase (BuChE). The two forms differ genetically, structurally, and
for their kinetics. Butyrylcholine is not a physiological substrate in mammalian brain, which
makes the function of of difficult interpretation. In human brain, BuChE is found in neurons and
glial cells, as well as in neuritic plaques and tangles in AD patients. Whereas, AChE activity
decreases progressively in the brain of AD patients, BuChE activity shows some increase [9].
The Tau Hypothes
Tau is a microtubule-associated protein (MAP) required for stabilizing microtubules
and neurite outgrowth [10]. Normal Tau interacts with tubulin, facilitates its assembly into
microtubules and stabilizes their structure [11]. Tau-based neurofibrillary pathology is found
in more than 20 neurodegenerative diseases. Phosphorylation of Tau within the microtubule
binding repeats (R) is necessary for appropriate neurite outgrowth. The ratio of 3R and 4R
Tau isoforms is generally 1:1 in the adult brain, but deviations from this ratio may cause
Tauopathies (Tau pathologies) [12]. Hyperphosphorylated Tau spontaneously aggregates into
paired

helical

filaments

(PHF),

which

can

subsequently

form

NFTs.

In

AD,

hyperphosphorylated Tau accumulates, prompting its dissociation from microtubules, thus
leading to their destabilization and the disruption of neuronal transport.
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The Amyloid Hypothesis:
One of the hallmarks of AD is the accumulation of amyloid plaques between nerve cells
(neurons) in the brain. The amyloid hypothesis indicates that is accumulation leads to a chain of
events that culminate the AD pathology. These events damage synapses and neurons thereby
producing neuroinflammation, neurodegeneration, loss of synapses, formation of neurofibrillary
tangles and aggregation of beta amyloid (Figure 1). Amyloid are protein fragments that the body
produces normally. Beta amyloid is a protein fragment cleaved from an amyloid precursor
protein (APP), which are involved in neuro-genesis and neural development. In a healthy brain,
these protein fragments are broken down and eliminated [13]. In AD, the fragments accumulate
to form hard, insoluble plaques.
The cleavage of APP takes place at the N-terminal of a beta amyloid sequence, this
gives rise to a C -terminal APP fragment, C99 and a large secreted N-terminal product called
sAPP-β. The sAPP-β is a soluble fragment. C99 is further cleaved by gamma secretase
(containing catalytic subunits; presenilin, Aph-1, Nicastrin, and Pen-2 protein) forming a beta
amyloid fragment and an APP intracellular domain (AICD) [14]. The end result is beta
amyloid (Aβ), a peptide of amino acids ranging from 36 to 43, the main component of
amyloid plaques. Aβ40 is soluble and turns out to be the most abundant species accounting for
90% of the total Aβ peptide in normal brains and AD brains. Aβ42 is the primarily abundant
in patients presenting with AD. Aβ42 possess 2 hydrophobic ends therefore this species has a
very high propensity for clustering or aggregating. It forms toxic oligomers which facilitate
the formation of plaques [15]. The accumulation of Aβ42 is highly due to mutations in
presenilin genes present in vertebrates (which encode for PS-1 and PS-2) which are key
catalytic subunits of gamma secretase intramembrane protease complex (Figure 3). The
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mutations in presenilin genes and APP play a major role in the accumulation of Aβ42 which
subsequently leads to the formation of fibrils and eventually neurotoxity or cerebral beta
amyloidosis [16]. These mutations predominantly accounts for the presentation of early onset
AD which is referred to as familial AD. In AD patients the amyloid accumulation drives the
deposition of the plaques because it happens to be the main component protein of the plaque.
This subsequently causes formation of neurofibrillary tangles, neuronal loss, vascular damage
and dementia. The severity of AD is directly proportional to the amount of amyloid plaque
accumulated [17]. The aforementioned process describes the amyloidogenic processing of
APP. It should be noted that physiologically beta amyloid peptides are generated at low
concentrations and that a significant amount of APP is processed via the non-amyloidogenic
pathway that involves cleavage of APP by alpha secretase.
Now the alpha site of APP is cleaved by alpha secretase (comprising of members of the
disintegrin and metalloproteinase; ADAM family) producing C83, an α-secretase-generated Cterminal APP fragment (α-CTF) and N-terminal portion of APP (soluble APP-α; sAPP-α) [18].
The fragment, α-CTF undergoes further processing by the γ-secretase complex to generate
AICD and p3 peptides. sAPP-α is found to be neurotrophic and neuroprotective properties [19].
Studies have revealed that the suppression of sAPP-α by conditions such as oxidative stress,
abnormal lipid metabolism, abnormal glucose metabolism, physical inactivity, and cerebral
hypoperfusion can lead to sporadic AD (SAD). sAPP-α is highly being considered for potential
therapeutic properties [20]. It is unquestionable that the AD pathology is mostly due to the
accumulation of Aβ and inhibition or suppression of sAPP-α .rather than altered expression of
APP or its products, causes AD pathology.
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Figure 2: Generation of Aβ42

Epsilon 4 allele of the apolipoprotein E gene (APOE ε4):
Apolipoprotein E is a class of apolipoprotein that primarily break down and transport
triglycerides, cholesterol and beta amyloid. It is a polymorphic gene with three alleles; ε2, ε3
and ε4. The allele; ε2 is protective against AD but may increase or decrease risk of an
atherosclerosis diagnosis but it facilitates the metabolism of beta amyloid. The allele, ε3 is
considered the neutral allele of ApoE while the ε4 form is linked with a high risk of getting AD
[21]. ApoE-ε4 has been linked to late onset AD [17]. The allele, ε4 significantly increases the
chances of sporadic AD by 3 fold in heterozygotes and by 15 fold in homozygotes [22]. In the
presence of ApoE-ε4, there is a gain in toxic function due to inefficient metabolism of beta
amyloid. Therefore, an accumulation of beta amyloid which leads to a cascade of damaging
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processes which include decreased lipid metabolism, decrease in synaptic function , neuronal
toxicity, atrophy of the brain and increased aggregation of beta amyloid peptides [23].
1.2.1 SYMPTOMS OF ALZHEIMER’S DISEASE

Clinical experts have categorized the symptoms of AD to fall under mild cognitive
impairments. This includes significant attention deficits, decline in learning and memory,
decreased executive function, declined speed in processing information, and semantic language.
[24].

1.2.2 DIAGNOSIS OF ALZHEIMER’S DISEASE

Innovative early diagnostic tests have been developed to detect AD before symptoms
begin to

appear. One such test involves the analysis of cerebrospinal fluid for beta-amyloid or

tau proteins, [25] both total tau protein and phosphorylated tau181P protein concentrations.
Searching for these proteins using a spinal tap can predict the onset of Alzheimer's with
a sensitivity of between 94% and 100% [26][27]. When used in conjunction with
existing neuroimaging techniques, doctors can identify people with significant memory loss
who are already developing the disease [28]. Alzheimer's disease is usually diagnosed based on
the person's medical history, history from relatives, and behavioural observations. The presence
of characteristic neurological and neuropsychological features and the absence of alternative
conditions is supportive [29][30]. Advanced medical imaging with computed tomography (CT)
or magnetic

resonance

imaging (MRI),

and

with single-photon

emission

computed

tomography (SPECT) or positron emission tomography (PET) can be used to help exclude other
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cerebral pathology or subtypes of dementia [31]. Moreover, it may predict conversion
from prodromal stages (mild cognitive impairment) to Alzheimer's disease [32].
1.2.3 TREATMENT OF ALZHEIMER’S DISEASE

There is currently no cure for AD. The interventions are palliative in nature and cover three
categories of management of AD; psychosocial, pharmaceutical and caregiving.
Psychosocial: This intervention has insufficient data to proof its efficaciousness. It targets more
dementia than AD and it is administered as an adjunct to pharmaceutical intervention [33].
Psychosocial options include emotion-oriented interventions, behavioral interventions and
cognitive-oriented treatments [34].
Pharmaceutical: This method of managing AD borders on two approaches; inhibiting acetylcholinerase and N-Methyl-D-aspartate (NMDA). Four medications have been developed that
inhibit acetyl-cholinerase, they include tacrine, rivastigmine,galantamine and donepezil[35].
Unfortunately, none of the medical treatments listed can cure AD. In fact, the improvement due
to medical intervention are mild to moderate and last for 6 months to 1 year.
Nutritional: There has been several studies conducted showing the effect of bioactive
components of food on AD; omega-3 fatty acids, antioxidants or B vitamins, and dietary
patterns (Mediterranean diet) have demonstrated protective effects on age related chronic
diseases [36]. Cassia Obtusifolia, a botanical that has been traditional used to treat inflammatory
conditions and diseases of the liver and eye is currently being explored for neuro-protection in
AD [37]. It’s proposed mechanism of action in treating or preventing AD is through the
inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-site amyloid
precursor protein (APP) cleaving enzyme 1 (BACE1) enzyme activity. There is also the
possibility of treatment of AD with antioxidants due to the damaging effects of oxidative stress
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on nerve cells and synapses. The question of whether or not antioxidants play a role in treating
AD due to the effect of reactive oxygen species (ROS) which can subsequently lead to oxidative
stress is still being explored. The presence of oxidative stress can cause high concentrations of
protein oxidation, protein nitration, glycoloxidation and lipid peroxidation and the hallmark of
AD; accumulation of Aβ [38]. There is justification in experimenting on the effect of nutrition
high in antioxidants on AD.

1.3 NUTRITION AND ALZHEIMER’S DISEASE

Nutrition plays a role in the presentation of AD. Extensive studies have shown that
supplementation of the diet with antioxidant, B vitamins, polyphenols and polyunsaturated fatty
acids and increase in the ingestion of fish, fruits, vegetables, coffee and light to moderate
alcohol not only help treat AD but also reduce the risk of getting this disease, figure 3 [39].

Figure 3: Nutrition
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Foods and beverages that influence the incidence of AD. Fish, vegetables, fruits, coffee, and light-tomoderate alcohol intake are reported to reduce AD incidence. Milk and tea are reported to
influencecognition, but their influence on AD is not clear.

It is postulated that there is a correlation between the development of AD and oxidative
stress. The generation of Aβ could actually be protective in hiding sources of free radicals. The
accumulation of the Aβ as indicated earlier will induce AD as a result of insufficient or
inefficient clearing. Aβ accumulation can interfere with the normal electron flow through the
respiratory chain by binding to mitochondrial membranes and interacting with heme. This
subsequently leads to the production of reactive oxygen species (ROS) and diminished
mitochondrial energy metabolism. This could justify the hypometabolism observed in patients
with AD [40]. Data collected from studies conducted with flavonoid and non-flavonoid
polyphenols have show promise in neutralizing excess ROS thereby suppressing their damaging
effects.
Although there is limited data on the mechanism of action of antioxidants in AD,
neuronal protection and potent scavenging of singlet oxygen, superoxide anions, hydroxyl
radical and peroxyl radicals have been shown with the ingestion of epigallolcatechin (EGCG),
resesveratrol and curcumin. The scientist, Schroeder demonstrated the effect of EGCG on the
integrity of neuronal function on rat models and discovered selective protection of the rats
cultured cerebullar granule neurons from oxidative stress [41]. EGCG has also shown protection
from toxicity resulting from beta amyloid precursor protein (APP), 3-hydroxykynurenine, or 6hydroxydopamine (6-OHDA) in SH-SY5Y human neuroblastoma cells [42]. Resveratrol
(trans-3,4′,5-trihydroxystilbene) is the key non-flavonoid polyphenol that can be extracted from
grapes and found in red wine. It has anti-inflammatory, anti-carcinogenic and antioxidant
activities [43]. Beta amyloid induced intracellular accumulation of reactive oxygen species was
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attenuated by resveratrol [44]. In vivo studies have also reported attenuation of the degeneration
of neurons in the hippocampus of the inducible p25 transgenic mouse model of AD and
tauopathy by reseveratrol [45].
1.3.1 CURCUMIN
Curcumin (diferuloylmethane) is a popular Asian spice is derived from Curcuma longa,
turmeric. Over many years in has been utilized medicinally as a remedy for wound healing,
inflammation and even as an anticarcinogen [46]. Epidemiological studies have revealed
correlation between cognitive function and the intake of curcumin. One of these studies pulled a
total of 1010 Asians between 60 and 93 years of age and subjected them to a standard test,
MMSE that measures cognition. The subjects were placed into groups that consumed curry
less frequently (less than once a month), rarely consumed curry and the consumed curry more
often (more than once a month). The result of the study showed higher MMSE score for the
group that consumed curry more often compared to those you either eat less or never eat curry
[47]. Extensive research have shown that curcumin acts as an antioxidant, playing a major role
in combating oxidative stress and health conditions related to oxidative stress like diabetes,
obesity, cardiovascular disease and AD. It has shown to be a potent scavenger of different
reactive oxygen species; like superoxide anion radicals, hydroxyl radicals [48], and nitrogen
dioxide radicals [49][50]. It has been theorized that curcumin stimulates the activation of stress
sensitive kinases in fructose fed rats by inhibiting phosphorylation of the kinases, thereby
preventing cell damage [51]. A summary of the various revealed mechanisms of action of
curcumin is displayed in figure 4. Studies conducted on cultured neuroblastoma cells focused on
the effect of curcumin on the in vitro expression of PS1 and the enzyme glycogen synthase
kinase-3, GSK-3β. GSK-3β presentation has been linked to the development of AD and

14

presenilin-1 has been identified as its substrate. Curcumin was reported to be successful in
blocking the stimulation of presenilin-1 activity by GSK-3β, thereby reducing the production of
beta amyloid peptides [52]. In addition, studies conducted at UCLA revealed that curcumin
facilitates the metabolism or clearance of beta amyloid plaques in AD by macrophages [53].
This justified our use of curcumin as a positive control in our research.

Figure 4: Various mechanisms of action of curcumin

1.4.1 OIL PALM PHENOLICS
Oil palm (Elaeis guineensis) is predominantly found in the tropics and contains a high
concentration of water soluble phenolics. It is a high oil-producing tropical plant that appears to
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have an effective anti-oxidative component to counter the oxidative stress exerted by high
temperature and intense sunlight [54].
An estimate of 85% of the world's palm oil consumed as food. This has lead to further research
on the nutritional contents and benefits of this food product. Oil Palm contains almost 50%
saturated fatty acids (SFA). This percentage has presented in key area of research in
determining its efficacy in relation to heart related diseases like coronary heart disease (CHD)
risk. The constituents of oil palm are 44% Palmitic acid (44%), the key SFA in palm and
monounsaturated oleic acid (39%) and polyunsaturated linoleic acid (11%).
In addition to the fatty acid component of oil palm, there is also a phytochemical
component. Oil palm contains carotenoids, tocopherols, tocotrienols, sterols, squalene,
coenzyme Q10, phospholipids, and polyphenols. The presence of these phytochemicals ensures
the quality and stability of the oil [55]. Apparently, all the phytochemical present in palm oil
possess antioxidant properties. Oil Palm Phenolic (OPP) or the palm juice is the aqueous stream
extracted from oil palm that is rich in phenolic antioxidants. The therapeutic effects of OPP on
cardiovascular diseases, diabetes and cancers have been reported by Sambanthamurthi et al
[56]. They concluded that OPP could be used as a dietary agent for prevention of many
oxidative stress related chronic diseases, including neurodegenerative ailments. Plant phenolics
are major antioxidants due to their high redox potential which causing them to be effective as
reducing agents, hydrogen donors, singlet oxygen quenchers and chelators for metals.
Antioxidants that accumulate in neuronal tissues are potential candidates for the prevention and
treatment of neuronal disorders involving oxidative stress [57]. As a result of extensive research
that has revealed the neuroprotective potential of OPP and the finding that the hallmark of
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Alzheimer disease is neuroinflammation and oxidative stress impacting neurotoxicity, we test
the impact of OPP on rats fed a high fat diet using curcumin as the positive control.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Animals and diets
32 in-bred Brown Norway (BN) rats were obtained from the aged rodent colonies of the National
Institute of Aging (Bethesda, MD). Since effects of estrogen on cholesterol metabolism might
alter Aβ, we used male rats for this study. Upon arrival, 12 rats were 22 weeks old and 20 rats
are 24 weeks old. They were assigned to 4 groups on a pseudo-random basis with the constraint
that all diet groups had the same mean body weight. Four groups were named by their diets:
control diet (n = 8), High fat diet (n=8), High fat with OPP (n=8) and High fat with Curcumin
(n=8). The diet compositions are summarized in Table 1. Diets for four groups contained similar
level of calorie. The purified diets were obtained in pelleted form from Dyets Inc. (Bethlehem,
PA), and sufficient diet was obtained for the entire duration of the study. The diets were kept at 20°C, and sufficient diet was removed weekly as needed and kept refrigerated at 4°C. Animals
were fed ad libitum and had free access to tap water.
Briefly, twice weekly food intake and weekly body weight were recorded to monitor health
status (Table 2). Urine samples of each rat were collected once a month for urinary metabolomic
profiling. Once a month, all rats were subjected to a five-day test of spatial learning/memory
using Morris’s water maze. Monthly urine collections were carried out for a urinary metabolomic
study. All procedures and protocols were in accordance with and ratified by the Animal
Investigation Committee of Wayne State University.
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Table 1: Composition of purified diets
Ingredient

isocaloric Control

High Fat (2% Cholesterol)

High Fat+5% OPP

High Fat+ 2%Curcumin

g/kg
Casein

140

140

140

140

L-Cystine

1.8

1.8

1.8

1.8

Sucrose

100

77.5

77.5

77.5

Cornstarch

465.692

465.692

415.692

445.692

Dyetrose

155

155

155

155

Soyabean oil

40

40

40

40

t-butylhydroquinone 0.008

0.008

0.008

0.008

Cellulose

50

50

50

50

Mineral

35

35

35

35

10

10

10

10

Choline Bitartrate

2.5

2.5

2.5

2.5

Cholesterol

_

20

20

20

Cholic Acid

_

2.5

2.5

2.5

OPP

_

_

50

_

Curcumin

_

_

_

20

Total(g)

1000

1000

1000

Mix#210050
Vitamin
Mix#310025

Diets were prepared and pelleted by Dyets Inc. (Bethlehem, PA).

1000
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Table 2: Study timeline based on the overall study
Procedures

Frequency of Measurement

Body weight, diet intake, water intake

Twice weekly (Week 1-6)

Urine collection

Once weekly (Week 2,4,6)

Blood and tissue collection

End of study (Week 6)___

2.2 Spatial Learning Test
A Morris Water Maze test (MWM) was conducted to examine spatial learning and
memory. Rats were tested in a circular pool, 60 inches in diameter and 30 inches deep, filled
with 10 inches of water made opaque by the addition of a non-toxic dye and maintained at 2425o C. The swimming pool was placed in a room surrounded by fixed spatial cues such as
posters, floor lamp and desk. The rats were trained to locate the hidden escape platform
submerged in the water. Latencies for rats to find the platform (sec) were analyzed as a measure
of spatial learning. The Rats were given 3 trials/day for 5 consecutive days. Rats were allowed
90 s to swim around the pool and find the hidden platform. If the rat did not find the platform
within this time, it was gently rescued from the water and placed on the platform. Each trial was
separated by 45 min. The platform was always located in the same fixed spot during training and
the starting point also remained the same among the trials for each rat. All trials were recorded
by a video camera mounted above the pool and the behavioral measures were acquired by a
computerized video-tracking system (EthoVision 2.0, Noldus Information Technology,
Leesburg, VA).
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2.3 Tissue collection
All rats were sacrificed by decapitation. Trunk blood was collected into K2EDTA coated
tubes and kept on ice. Organs were excised and wet weight was recorded prior to flash freezing
in liquid nitrogen. Brain was extracted immediately (generally within 3-5 minutes) and the left
hemisphere was flash frozen in liquid nitrogen. Right hemispheres of all rats were immersionfixed in 10% neutral buffered formalin (Fisher Scientific International) for 48 hours and then
were transfer to 70% Ethanol before staining. Hippocampus and cerebral cortex were extracted
from the rest of the right hemispheres and fixed in RNAlater (Ambion, inc. Austin, TX) for RNA
extraction.

2.4 Histology
All the right hemisphere brain tissues preserved in 10% neutral buffered formalin were
sent to Histology lab, Division of Human Pathology, Michigan State University for Hematoxylin
and eosin stain (H&E) staining and Congo red staining. Nuclei were counter stained by H&E for
visualizing the morphological changes of the neurons. Congo red staining was performed to
visualize extracellular amyloid deposition in the hippocampus on the brown Norway rats. All the
slides were observed under the microscope (Nikon Eclipse 80i).

2.5 Enzyme-linked Immunosorbent Assay
This assay involves a two part process; firstly the whole tissue extraction and running the
assay. The Colorimetric BetaMark x-42 ELISA kit was purchased from Covance (Princeton,
New Jersey, USA). All the reagents, standard dilutions, control and samples were reconstituted
according Covance protocol. The whole brain tissues of all the rats in the four groups; control
(C), high cholesterol (H), high cholesterol and oil palm phenolics (HP) and high cholesterol and
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curcurmin (HC) were homogenized individually in TBS with protease inhibitors and EDTA.
70% formic acid was added to the homogenate, to mix we agitated the tissue by pipetting up and
down. We spun the mixture of each group for 20 minutes at 350,000 g. The supernatant which
represents the whole brain extract was retrieved for the assay. The supernatant was stored in -80֯
C. To start running the assay the sample were removed from -80֯ C and thawed on ice. 300 µL of
1X wash buffer were added to each well, then dumped out after which the plate is pat dried on
clean paper towel. On day 1, 50µL of each standard was added to the plate in triplicate. 50µL of
each sample was added in triplicate as well as 50 µL to each well of diluted HRP detection
antibody. The plate was then covered with a plate sealer. The plate was mixed on a plate shaker
for one minute and then incubated overnight at 8֯C. On day 2, the plate was removed from the
refridgerator and the contents are dumped out. The plate was then washed with 300µL of 1X
wash buffer per well. The buffer was then dumped and the plate pat dried with clean paper towel.
The plate was washed repeatedly with the 1X wash buffer 4 more times for a total of 5 washes.
200µL of TMB substrate was added to each well. The plate was then incubated for 50 minutes at
room temperature in the dark. The optical density of each plate was determined using a Bio-tek
Elx800 micro-plate reader set at a wavelength of 620nm. The concentration of the unknown
(β42) was calculated using the standard curve.

2.6 Statistics
All statistical analyses were performed using SPSS 15.0 for Windows® and
SmartWiewerTM, (SPSS Inc. Chicago, IL). Data were analyzed using one- or two-way ANOVA
with the age and diet as between-subject factors followed by Tukey post-hoc tests. Comparisons
between the diets in the same age group were analyzed using student t-test. For MWM test, the
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trial day was the repeated within-subject factor and diet was the between-subject factors. Results
are presented as the means ± SEM.
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CHAPTER 3
RESULTS
3.1 DIET AND WATER MAZE
We were successful in feeding the rat models isocaloric diets across the control, high cholesterol,
high cholesterol and OPP, high cholesterol and curcumin groups. There was no significant gain
or loss of weight during the 23 week period of feeding and weighing of the animal models
(figure 5 and 6). The Morris water maze experiment revealed longer escape latency time initially
for the high cholesterol group but this improved from day 3 (figure 7). Subsequently, we
observed significant improvement in escape latency time when month 1 was compared to month
5 (figure 8).
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Figure 5: Mean dietary Intake per group consumed at week 1 and week 23.
Results represent mean + SE.
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Figure 6: Mean body weight of rats per group at week 1 and Week 23.
Results represent mean + SE.
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Figure 7: Escape Latency times at month 1 of Morris water maze.
* P < 0.05 when compared with control group. Statistical analysis ANOVA with Tukey’s procedure was
used SPSS software
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Figure 8: Morris Water Maze.
Improvement in Escape Latency (EL) using Morris water maze test in the OPP fed group (HP) from month 1 (M1) to
month 5 (M5) of the study.

3.2 HISTOLOGY AND ELISA
When viewed under the Nikon microscope the H & E stained slides reveal more dead
neurons and neuronal in the control and high cholesterol group compared to the control, high
cholesterol +OPP and high cholesterol+ curcumin groups (p<0.05) (figure 9). We also noticed a
higher concentration of dead neurons in the CA1 zone of the hippocampus. A significant
decrease in healthy neurons was observed in the high cholesterol group (figure 10). The high
cholesterol group contained the highest area of beta amyloid plaque deposition (figure 11).
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Figure 9: Dead Neurons.
This figure shows the presence of dead neurons (pyramidal shaped, intensely colored) in the hippocampal
areas; CA1, CA3 and DG of the animal groups; C= Control, H=High Cholesterol, HP= High Cholesterol+
OPP, HC= High Cholesterol+ Curcumin

The Congo red stained slides detected extracellular plaque formation, predominantly in the high
cholesterol group as observed through the microscope. Plaque deposition in the control group
was negligible (figure 12). High cholesterol diet induced plaque was visualized in the high
cholesterol group, high cholesterol + OPP group and high + curcumin group (figure 13, 14 and
15).
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In addition, the congo red stained slides showed that the high cholesterol group had the
highest average plaque load (% hippocampus area) compared to other two supplemented high
cholesterol diet (Figure 16 and 17). ELISA was performed to identify the amyloid peptide and
quantify the beta amyloid plaque that was observed (Figure 18).
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Figure 11: Sum of the area of individual plaque concentration in each group
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Figure 12: Congo Red stained slide of the Control group (C) revealing negligible traces of amyloid
plaques.

Figure 13: Congo Red stained slide of the High Cholesterol group (H) showing traces of amyloid
deposition, indicated by the arrows.
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Figure 14: Congo Red stained slide of the High Cholesterol + OPP group (HF) showing few traces
of amyloid deposition, indicated by the arrows.

Figure 15: Congo Red stained slide of High Cholesterol + curcumin group (HC) showing few
traces of amyloid plaques, indicated by the arrows.
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Figure 18: The concentration of β-amyloid 42 quantified via ELISA
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CHAPTER 4
4.1 DISCUSSION
This study is part of a broader experiment being conducted by a PhD student focusing on
the invivo effect of OPP on atherogenic diet induced rat models (figure 19). The goal of my
study is to show histological evidence of the impact that a diet containing OPP will have on beta
amyloid deposition in the hippocampus of aged Brown Norway rat model induced by a high fat
diet. The results of our study is closely linked to that of Tara L Spires et al and West MJ et al
were it was observed that selective damage seemed domicile in the CA1 zone compared to the
CA3 zone. In our study dead and degenerated neurons were noticeable in the control and high
cholesterol only group as depicted by the absorption of the dark blue dye vie H and E staining ;
which histologically represents a diseased or dead neuron [41][42]. Congo red stain is a
diagnostic tool for amyloidosis, it functions by binding to amyloid fibrils which can subsequently
be observed under a microscope [43][44]. Congo red staining enabled visualization of
extracellular amyloid deposition in the hippocampus.
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Figure 19: LAYOUT OF STUDY

In our study the control group showed minimal presence of amyloid deposition, this should not
be the case because aging should impact the normal metabolism of beta amyloid peptides.
Therefore, there should have been some accumulation of beta amyloid plaques in the
hippocampus in the control group. This is an exception. It is likely that viewing the slides under
the microscope failed to capture the plaque load in the control group because the ELISA
conducted revealed plaque load in the control group. The ELISA proved to be a more sensitive
and specific test due to its ability to reveal the hydrophobic beta amyloid peptide load undetected
by Congo red staining. It could also be possible that the amyloid plaques observed were strictly
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due to intake of the high cholesterol diet. Other epidemiology studies have revealed that
ingestion of diets high in fat and cholesterol can be linked increased cases of dementia. In these
studies the form of fat responsible for the presentation of AD tended to be saturated in nature
[45]. Linoleic acid which is a form of omega-6-polyunsaturated fat was not linked to AD.
Although the mechanism in which high cholesterol diet impacts cognitive function is yet to be
known, it has been proposed by other extensive research that activation of protein kinase C and
phosphorylation of protein F by high unsaturated fat lead to higher memory storage as a result of
increased synaptic plasticity. In addition other studies have shown that cholesterol lowering
drugs decreased the deposition of beta amyloid and othe AD related disease states. [46][47]. In
our study, high fat diet had successfully induced the AD-like pathologies both behaviorally (i.e.
Learning /memory deficits) and histologically (i.e. Aβ plaque formation in hippocampus). In
addition, aging might also serve as a factor by accelerating the AD pathology, given the fact that
all of our rats arrived at 22-24 month of age. So the elevated peripheral hypercholesterolemia and
a higher liver and brain cholesterol observed by my colleagues working on this project could
accelerate memory and brain damage, which confirm the opinion that high cholesterol diet is one
of the risk factors that cause AD-like brain metabolic changes. In the current study,the aged rats
amplified the effects of the diet in the model. It can be clearly put that our diet treatment
effectively created hypercholesterolemia condition in the Brown Norway rat model and this
effect was synergistically accelerated by aging effect. The test botanical, OPP clearly diminished
not only the beta amyloid peptides but was neuro-protective since histologically more healthy
neurons were observed in the rats that ingested this phenolic substance. The results seen in the
rats fed OPP plus high cholesterol were similar to that of the curcumin fed group which served as
our positive control. Curcumin was well suited as our positive control since literature has
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reported its ability to prevent Aß fibril plaque formation and protect the neurons from being
attacked by Aß oligomers and fibrils [48]. Curcumin has been widely studied for its clinical
benefits as an anti-inflammatory agent, an anti-amyloidogenic, an antioxidationt and an
anticarcinogen [49]. In previous studies, curcumin has been successful in suppressing the proapotoptic action of vasoactive peptide endothelin-1 (ET-1) which is increased in the human brain
tissue presented in AD pathology [50]. It’s mechanism of action facilitating this inhibition of ET1 is still being researched. The anti-inflammatory, anti-oxidant and anti-amyloidogenic
properties of curcumin have also been tested in a study performed in transgenic mice, Tg2576
that were provided a curcumin diet for 6 months [51]. It was observed that there was a significant
reduction in IL-1β, GFAP (an astroglia marker), plaque load , soluble and insoluble beta amyloid
peptides. Based on the aforementioned studies, we utilized curcumin as a positive control to test
the neuroprotective properties of OPP. There is limited data on the effect of OPP in AD but it has
been reported to possess anti-diabetic, anti-carcinogenic and antioxidant properties [52]. To test
for possible cardioprotective effects of OPP, Sambanthamurthi et al. carried out in vitro LDL
oxidation studies and they found that OPP inhibited the Cu-mediated oxidation of human LDL. It
was concluded that OPP have an antioxidant protective role against free radical damage, which
represents a new source of phenolic bioactives [49]. In order to test its neuro-protective effects,
Leow et al. fed the mice model; BALB/c with an OPP infused diet and then investigated the
effects of OPP on cognitive and motor functions. It was observed that better cognitive function
and spatial learning was achieved when tested in a water maze. That study proposed that OPP
can improve the neuron damage by up-regulating the genes involved in the regulation of the
neurotrophic factor and meanwhile, down-regulating the genes involved in inflammation [50].
The main limitation of this study was the challenges faced with the microscope used to visualize
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the congo red stained species and the reality that more research needs to be conducted using
OPP. In addition, it is quite clear that we are yet to conduct transcriptomic analysis on the brains
and then identify the gene expression changes. This will generate clues to help explain how OPP
confers these neuro-protective effects. This study was meant to be exploratory rather than
confirmatory , there are currently no extensive studies to demonstrate the effects of OPP on the
high fat induced AD animals.

4.2 Conclusion
Data from the histological analysis and ELISA in this study did demonstrate that high fat
diet induced beta amyloid deposition in the hippocampus. The neurotoxic species, Aβ42, was
clearly prominent in the high cholesterol group and noticeably reduced in the rats fed high
cholesterol plus OPP and curcumin respectively. OPP has significant neuro-protective properties
as it effectively improved the spatial learning abilities of rats on high cholesterol diet. These
improvements correlate to its neuron protective effect and its ability to lower amyloid load in
hippocampus. Based on our study results, OPP can improve cognitive impairment, reduce neuron
loss and decrease beta amyloid deposition in the hippocampus. Findings from this study has
provided evidence for more research to geared towards investigating genetic regulation pathways
and other innovative strategies to address the impact of OPP in AD models. It may also be noted
that since late onset AD accounts for about 87% of this form of dementia, more studies can be
conducted to investigate the impact of OPP on ApoEε4.
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ABSTRACT
HISTOLOGICAL EVIDENCE OF THE EFFECT OF OIL PALM
PHENOLICS IN ATHEROGENIC DIET INDUCED RAT MODEL OF
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BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disease with the clinical
presentation of memory loss and cognitive impairment. Alzheimer's disease pathology is the
accumulation of beta amyloid plaques and neurofibrillary tangles.
METHOD: In this study atherogenic diet was used to induce AD in aged Brown Norway rats.
The rats were assigned to the following four groups fed isocaloric diets; control group (C ),high
cholesterol diet (H), high cholesterol + oil palm phenolics group (HP), high cholesterol +
curcumin group (HC). The impact of oil palm phenolics (OPP) on neuronal health and its effect
on amyloid deposition was evaluated using histology and ELISA. The cognitive ability of the
rats were tested using Morris water maze.
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RESULTS: Our model was successful in facilitating the formation of extracellular beta amyloid
plaques and causing neuronal loss. Histological findings revealed better neuronal health in the
group of rats offered OPP in their diets compared to the high cholesterol only fed rats. The
Morris water maze test showed better learning and cognition in rats fed the OPP diet.
CONCLUSION: OPP provided neuronal protection and decreased the deposition of beta
amyloid plaques in the hippocampus of the rats.
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